Site icon AfricaReinvented

Nigeria Plans To Roll Out Oxford-AstraZeneca COVID-19 Vaccine Soon

AstraZeneca COVID-19 Vaccine in Nigeria

AstraZeneca COVID-19 Vaccine in Nigeria

AstraZeneca COVID-19 Vaccine in Nigeria

Nigeria’s health ministry has said that it is expecting the first batch of COVID-19 vaccine in the country soon as the COVAX group finally agrees on AstraZeneca.

In accordance with the COVAX programme, Nigeria will get a first 15 million doses of Oxford-AstraZeneca COVID-19 vaccine.

The Minister of Health, Dr Osagie Ehanire who disclosed the news during the national briefing of the Presidential Task Force on COVID-19 did say that the vaccine will be in Nigeria in February. However, there is no information on when the shots will begin.

He also said that the ministry is reviewing plans “to ensure a smooth roll out” of the vaccine in Nigeria.

According to the minister, Nigeria will get more doses of the AstraZeneca COVID-19 vaccine after the first 15 million to meet the quantity – 42 million doses – which the AU’s African Vaccines Acquisition Task Team AVATT assigned to it.

African Union COVID-19 Vaccine

The African Union is playing a role in COVID-19 vaccine for Africa as back up for the COVAX programme.

Nigeria’s National Primary Health Care Development Agency has applied to the AU to receive 40 million COVID-19 vaccines as well as from Russia and India according to the head of the National Primary Health Care Development Agency (NPHCDA), Dr Faisal Shuaiba to Reuters in January.

The chief also stated that Nigeria is going to avoid cold dependent COVID-19 vaccine like that of Phizer/BioNtech. It requires a huge sub-zero (-70°C or -112°F), special purpose cooling boxes loaded with ice for its transportation.

AstraZeneca Vaccine in Nigeria

AstraZeneca is a British–Swedish multinational pharmaceutical and biopharmaceutical company whose version of the COVID-19 vaccine is 62% effective with two shots. It is easier to distribute as it can be stored in a normal refrigerator.

The vaccine was approved by the MHRA, the UK’s regulatory body on 30 December.

Follow us on Facebook and Twitter.

Exit mobile version